Update on Risankizumab for Psoriasis
- 15 Downloads
Purpose of Review
This review highlights the latest data on risankizumab, including efficacy and safety data from recent clinical trials.
In multiple phase 3 clinical trials, risankizumab was shown to be safe and efficacious. Risankizumab demonstrated superior efficacy to leading active comparators for the induction and maintenance of clear skin and was shown to have a safety profile similar to other biologic therapies currently on the market.
Targeted biologic medications for plaque psoriasis have provided insight into the complex immune pathways that are now understood to lead to the development of several autoimmune diseases including plaque psoriasis. Risankizumab, a novel, fully human monoclonal antibody against the IL-23p19 subunit, is currently under investigation for the treatment of moderate-to-severe plaque psoriasis and shows promise to provide complete and lasting skin clearance with convenient dosing for patients. Future studies are needed to explore the long-term safety and efficacy of risankizumab beyond 5 years of therapy.
KeywordsPsoriasis Risankizumab Biologic IL-23 Efficacy Safety
Compliance with Ethical Standards
Conflict of Interest
Mark Lebwohl is an employee of Mount Sinai and receives research funds from: Abbvie, Amgen, Arcutis, Bausch Health (Valeant), Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Johnson & Johnson (Centocor, Janssen), Leo Pharmaceutucals, Medimmune/Astra Zeneca, Novartis, Pfizer (Anacor), Regeneron, Sciderm, UCB, Inc., and ViDac. Dr. Lebwohl is also a consultant for Allergan, Aqua, Arcutis, Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, LEO Pharma, Menlo, Mitsubishi, Neuroderm, Promius/Dr. Reddy’s Laboratories, Theravance, and Verrica.
Dr. Bares has nothing to disclose.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 9.Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Targeting IL-23 in psoriasis: current perspectives. Psoriasis (Auckl). 2018;8:1–5.Google Scholar
- 10.• Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116–124.e7 This study demonstrated that risankizumab was well tolerated and associated with substantial clinical response at week 12 compared with placebo. CrossRefGoogle Scholar
- 11.•• Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2017;376(16):1551–60 This study showed that risankizumab was well tolerated and associated with a clinical response superior to ustekinumab at 12 weeks. CrossRefGoogle Scholar
- 12.•• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61 This study demonstrated the efficacy of risankizumab is more rapid and superior to that of ustekinumab through 1 year while having a similar safety profile and equally convenient dosing. CrossRefGoogle Scholar
- 13.Abbvie. Risankizumab meets all co-primary and ranked secondary endpoints, achieving significantly greater efficacy versus standard biologic therapies in three pivotal phase 3 trials. https://news.abbvie.com/news/risankizumab-meets-all-co-primary-and-ranked-secondary-endpoints-achieving-significantlygreater-efficacy-versus-standard-biologic-therapies-in-three-pivotal-phase-3-psoriasis-studies.htm. Published 26 October 2017. Accessed 30 August 2018.
- 14.Abbvie. Risankizumab meets all primary endpoints reporting positive results in fourth pivotal phase 3 psoriasis study. https://news.abbvie.com/news/press-releases/risankizumab-meets-all-primary-endpoints-reporting-positive-results-in-fourth-pivotal-phase-3-psoriasisstudy.htm. Published 4 December 2017. Accessed 30 August 2018.
- 15.Abbvie. Abbvie submits biologics license application to U.S. FDA for investigational treatment risankizumab for moderate to severe plaque psoriasis. https://news.abbvie.com/news/abbvie-submits-biologics-license-application-to-us-fda-for-investigational-treatment-risankizumab-for-moderate-to-severeplaque-psoriasis.htm. Published 25 April 2018. Accessed 30 August 2018.